Leukoaraiosis in Neurodegeneration

Leukoaraiosis in Neurodegeneration

Introduction

Leukoaraiosis (LA) refers to bilateral hyperintensities of the white matter on T2-weighted magnetic resonance imaging (MRI) scans, representing white matter lesions (WMLs) or white matter hyperintensities (WMHs). Initially considered an incidental finding of aging, leukoaraiosis is now recognized as a significant contributor to cognitive decline and neurodegenerative disease progression. [@debette2010]

Definition and Imaging

Leukoaraiosis appears as patchy or confluent areas of increased signal intensity on T2-weighted and FLAIR MRI sequences, predominantly located in the periventricular and deep white matter. The Fazekas scale (0-3) is the most widely used grading system: [@pantoni2010]

• Periventricular hyperintensities (PVH): 0 = absent, 1 = caps or rim, 2 = smooth halo, 3 = irregular hyperintensities extending into the deep white matter
• Deep white matter hyperintensities (DWMH): 0 = absent, 1 = punctate, 2 = early confluence, 3 = large confluent areas

Vascular Risk Factors

Leukoaraiosis is strongly associated with cerebrovascular disease risk factors: [@wardlaw2021]

| Risk Factor | Association with LA | [@prins2015]
|-------------|---------------------| [@bilello2015]
| Hypertension | Strong positive correlation; duration and severity matter |
| Diabetes mellitus | Moderate association with WMH progression |
| Smoking | Dose-dependent increase in WMH burden |
| Hyperhomocysteinemia | Independent risk factor for WMH |
| Atrial fibrillation | Associated with increased LA severity |

...

Leukoaraiosis in Neurodegeneration

Introduction

Leukoaraiosis (LA) refers to bilateral hyperintensities of the white matter on T2-weighted magnetic resonance imaging (MRI) scans, representing white matter lesions (WMLs) or white matter hyperintensities (WMHs). Initially considered an incidental finding of aging, leukoaraiosis is now recognized as a significant contributor to cognitive decline and neurodegenerative disease progression. [@debette2010]

Definition and Imaging

Leukoaraiosis appears as patchy or confluent areas of increased signal intensity on T2-weighted and FLAIR MRI sequences, predominantly located in the periventricular and deep white matter. The Fazekas scale (0-3) is the most widely used grading system: [@pantoni2010]

• Periventricular hyperintensities (PVH): 0 = absent, 1 = caps or rim, 2 = smooth halo, 3 = irregular hyperintensities extending into the deep white matter
• Deep white matter hyperintensities (DWMH): 0 = absent, 1 = punctate, 2 = early confluence, 3 = large confluent areas

Vascular Risk Factors

Leukoaraiosis is strongly associated with cerebrovascular disease risk factors: [@wardlaw2021]

| Risk Factor | Association with LA | [@prins2015]
|-------------|---------------------| [@bilello2015]
| Hypertension | Strong positive correlation; duration and severity matter |
| Diabetes mellitus | Moderate association with WMH progression |
| Smoking | Dose-dependent increase in WMH burden |
| Hyperhomocysteinemia | Independent risk factor for WMH |
| Atrial fibrillation | Associated with increased LA severity |

Cerebral Small Vessel Disease

LA is the imaging hallmark of cerebral small vessel disease (CSVD):

Arteriolosclerosis: Lipohyalinosis and fibrinoid degeneration of small penetrating arterioles

[Blood-brain barrier](/entities/blood-brain-barrier) dysfunction: Increased permeability allows plasma proteins to leak into white matter

Chronic hypoperfusion: Reduced cerebral blood flow contributes to white matter damage

Venular abnormalities: Periventricular veins show decreased compliance

Pathological Features

• Diffuse white matter edema: Interstitial fluid accumulation
• Myelin pallor: Loss of myelin staining
• Axonal damage: Reduced axonal density
• Gliosis: Reactive astrocytosis
• Microinfarcts: Small foci of infarction in white matter

Impact on Neurodegeneration

Alzheimer's Disease

• Amyloid angiopathy connection: CAA often coexists with LA; both involve vascular amyloid deposition
• Accelerated cognitive decline: Patients with severe LA decline faster on MMSE and executive function tests
• Conversion from MCI to AD: Higher WMH burden predicts faster progression
• Network disruption: LA disconnects hippocampal-cortical networks essential for memory

Parkinson's Disease

• gait dysfunction: LA contributes to postural instability and gait freezing
• Executive impairment: Frontal white matter lesions impair executive function
• Visual hallucinations: LA severity correlates with hallucination frequency
• Dementia risk: PD patients with LA have higher risk of developing dementia

Vascular Dementia

• Direct contribution: LA is a core imaging feature of vascular cognitive impairment
• Strategic infarcts: Lesions in strategic white matter tracts cause disproportionate cognitive impact
• Mixed pathology: Most VaD cases show combined AD/vascular pathology

Imaging Biomarkers

Quantitative Measures

• Fazekas score: Semiquantitative visual rating
• Volumetric WMH: Automated segmentation provides precise volume measurements
• Diffusion tensor imaging (DTI): Reduced fractional anisotropy in normal-appearing white matter
• Perivascular spaces: Enlarged perivascular spaces correlate with LA severity

Prognostic Indicators

• Progression rate: Annual WMH volume increase >1 cm3 indicates rapid progression
• Location: Periventricular lesions predict cognitive decline better than deep lesions
• Confluence: Confluent lesions have worse prognostic implications

Therapeutic Implications

Vascular Risk Modification

| Intervention | Evidence |
|--------------|----------|
| Antihypertensive therapy | Reduces WMH progression; intensive control more effective |
| Statins | Mixed evidence; may slow progression |
| Antiplatelet therapy | Concern about bleeding risk; not clearly beneficial |
| Lifestyle modification | Exercise, smoking cessation, Mediterranean diet may help |

Cognitive Outcomes

• [Cholinesterase inhibitors](/entities/cholinesterase-inhibitors): Modest benefit in patients with mixed AD/Vascular pathology
• Vascular endpoints: Treating LA may prevent 20-30% of dementia cases
• Rehabilitation: Cognitive training may improve function despite white matter damage

Pathophysiological Mechanisms

Glymphatic System Dysfunction

The glymphatic system, the brain's waste clearance pathway, plays a crucial role in white matter health[@du2023]:

• Astrocytic water channels: AQP4 expression on astrocyte end-feet regulates fluid flow
• Perivascular clearance: Waste removal occurs along perivascular spaces surrounding penetrating arterioles
• Diurnal variation: Glymphatic activity is greatest during sleep
• WMH association: Glymphatic dysfunction contributes to WMH progression

Myelin Degeneration Patterns

White matter lesions show characteristic patterns of myelin loss[@chen2024]:

Periventricular pattern: Loss of myelin around lateral ventricles

Deep white matter pattern: Confluent lesions in centrum semiovale

Juxtacortical pattern: Subcortical lesions sparing U-fibers

Mixed pattern: Combination of above patterns

Inflammatory Mechanisms

Chronic inflammation contributes to WMH progression[@tertelman2024]:

• Microglial activation: Pro-inflammatory cytokine release
• T-cell infiltration: Adaptive immune response in WMH
• Cytokine storm: IL-1β, TNF-α, IL-6 in lesion progression
• Matrix metalloproteinases: Extracellular matrix degradation

Ischemic Mechanisms

Chronic hypoperfusion is a primary driver of WMH:

| Factor | Mechanism | Evidence |
|--------|-----------|----------|
| Arteriolosclerosis | Wall thickening reduces lumen diameter | Autopsy studies |
| Endothelial dysfunction | Reduced NO production | Animal models |
| Venular stiffening | Impaired drainage | Imaging studies |
| AV shunting | Altered flow patterns | Hemodynamic studies |

Clinical Presentation

Cognitive Deficits

Leukoaraiosis contributes to multiple cognitive domains:

Executive dysfunction:

• Impaired planning and organization
• Reduced processing speed
• Difficulty with multitasking
• Poor set-shifting ability

Memory impairment:

• Reduced episodic memory
• Impaired working memory
• Reduced verbal recall

Attention deficits:

• Reduced sustained attention
• Impaired selective attention
• Decreased divided attention

Gait and Motor Symptoms

White matter lesions commonly cause:

• Gait speed reduction: 30-50% slower than age-matched controls
• Balance impairment: Increased fall risk
• Gait variability: Inconsistent step length and timing
• Freezing of gait: Particularly in PD patients with WMH

Mood and Behavioral Changes

• Depression: Higher incidence in patients with WMH
• Apathy: Reduced motivation and initiative
• Emotional lability: Mood swings and irritability
• Psychosis: Less common but reported

Diagnostic Approaches

MRI Techniques

| Technique | Information Gained | Clinical Use |
|-----------|-------------------|--------------|
| T2/FLAIR | WMH visualization | Standard protocol |
| T1-weighted | Black holes (severe lesions) | Lesion severity |
| DTI | White matter integrity | Research |
| SWI | Microbleeds | CAA assessment |
| MRS | Metabolic changes | Research |
| ASL | Cerebral blood flow | Perfusion assessment |

Quantitative Analysis

Automated segmentation methods provide:

• Total WMH volume
• Regional WMH distribution
• Lesion count and size
• Progression rate over time[@deheyson2023]

Differential Diagnosis

WMH must be distinguished from:

• Multiple sclerosis lesions
• Vascular malformations
• Tumors
• Post-traumatic changes
• Normal aging (minor WMH)

Prognostic Factors

Poor Prognosis Indicators

• Rapid progression: >1 cm³/year volume increase
• Periventricular location: Worse than deep WMH
• Confluent lesions: Large confluent areas
• Associated microbleeds: CAA comorbidity
• Early age of onset: Younger patients progress faster

Protective Factors

• Lower baseline volume: Less room for progression
• Stable vascular risk factors: Controlled hypertension
• Active treatment: Ongoing risk factor management
• Physical activity: Preserved white matter integrity

Management Strategies

Lifestyle Interventions

| Intervention | Evidence Level | Recommendation |
|--------------|----------------|----------------|
| Aerobic exercise | Strong | 150 min/week moderate activity |
| Mediterranean diet | Moderate | Emphasize vegetables, fish, olive oil |
| Smoking cessation | Strong | Complete abstinence |
| Alcohol moderation | Moderate | Limit to 1 drink/day |
| Cognitive training | Moderate | Computer-based training |

Pharmacological Approaches

Antihypertensive therapy:

• First-line: ACE inhibitors, ARBs
• Target: <130/80 mmHg for CSVD
• Effect: Reduces WMH progression by 20-40%

Antiplatelet therapy:

• Aspirin for stroke prevention
• Caution in CAA (bleeding risk)
• Consider when >50% stenosis

Statins:

• Mixed evidence for WMH progression
• Strong evidence for cardiovascular protection
• Consider in high-risk patients

Cognitive enhancers:

• Donepezil: Modest benefit in VaD
• Memantine: May help vascular components
• Limited evidence for pure WMH

Emerging Therapies

• BPN14770: PDE4D inhibitor improving white matter integrity
• Mesenchymal stem cells: Promoting remyelination
• Anti-inflammatory agents: Targeting neuroinflammation
• Glymphatic enhancers: Improving waste clearance

Research Directions

Biomarkers

• Serum: Inflammatory markers (IL-6, TNF-α)
• CSF: Neurofilament light chain (NFL)
• Imaging: Advanced MRI metrics

Clinical Trials

• Treatments: Multiple ongoing trials for WMH
• Outcomes: Cognitive endpoints, MRI progression
• Design: Large cohort studies needed

Future Directions

Personalized medicine: Risk stratification based on genetics

Early intervention: Target pre-symptomatic WMH

Combination therapy: Multiple mechanism targeting

Precision treatment: Subtype-specific approaches

Vascular Cognitive Impairment

VCI Spectrum

Vascular cognitive impairment (VCI) represents a spectrum of cognitive disorders caused by cerebrovascular disease, with leukoaraiosis as a key imaging marker:

Subtypes:

• Vascular mild cognitive impairment (VaMCI): Pre-dementia stage
• Vascular dementia (VaD): Full dementia syndrome
• Mixed dementia: AD + vascular pathology

Post-Stroke Cognitive Decline

Leukoaraiosis predicts cognitive decline after stroke:

• Acute infarcts: Strategic location matters
• WMH burden:加重 post-stroke cognitive impairment
• Recovery: WMH slows functional recovery
• Recurrence: Higher stroke recurrence risk

WMH and Alzheimer's Disease

The relationship between WMH and AD is complex:

Shared risk factors:

• Age
• Hypertension
• APOE ε4 allele
• Diabetes mellitus

Interaction mechanisms:

• Amyloid-vascular intersection: Both processes may synergize
• Network disconnection: WMH disrupts memory circuits
• Blood-brain barrier: Shared dysfunction
• Glymphatic impairment: Reduced Aβ clearance

Imaging discrimination:
| Feature | WMH (Vascular) | AD |
|---------|----------------|-----|
| Location | Periventricular, deep | Posterior |
| Symmetry | Often symmetric | Often asymmetric |
| Microbleeds | Common (CAA) | Less common |
| Hippocampal atrophy | Mild-moderate | Severe |

Animal Models

Mouse Models

Chronic hypoperfusion models:

• Bilateral carotid artery stenosis (BCAS)
• Permanent bilateral common carotid artery occlusion (BCCAO)

Key findings:

• White matter damage develops over weeks
• Cognitive deficits correlate with WMH
• Glymphatic dysfunction precedes lesions
• Recovery possible with reperfusion

Limitations

• Species differences in white matter anatomy
• Difficulty modeling chronic progression
• BBB differences from humans
• Limited behavioral paradigm translation

Genetics

Susceptibility Genes

| Gene | Function | Effect |
|------|----------|--------|
| NOTCH3 | Vascular development | CADASIL |
| HTRA1 | Serine protease | CARASIL |
| COL4A1 | Basement membrane | Small vessel disease |
| ABCC6 | Transport protein | Pseudoxanthoma elasticum |

Polygenic Risk

• SNPs: Multiple variants contribute to WMH burden
• Heritability: 50-70% of WMH variance
• Interaction: Genes + environment determine risk
• Prediction: Polygenic scores under development

Prevention Strategies

Primary Prevention

Vascular risk factor control:

• Hypertension treatment (most effective)
• Diabetes management
• Lipid-lowering therapy
• Smoking cessation
• Weight management

Lifestyle factors:

• Regular physical activity
• Mediterranean diet
• Cognitive engagement
• Social interaction
• Sleep optimization

Secondary Prevention

After WMH detection:

• Intensify vascular risk control
• Monitor progression with MRI
• Treat underlying causes
• Address modifiable lifestyle factors

Tertiary Prevention

In established disease:

• Maximize function
• Prevent complications
• Optimize cognition
• Support independence

Economic Impact

Healthcare Costs

• High WMH burden: Associated with increased healthcare utilization
• Dementia conversion: WMH accelerates transition to dementia
• Caregiver burden: Correlates with WMH severity
• Long-term care: WMH increases nursing home placement

Cost-Effectiveness

• Early intervention: Most cost-effective
• Treatment targets: Blood pressure control high-value
• Monitoring: MRI surveillance cost-effective in high-risk
• Prevention: Population-level strategies cost-effective

Summary

Leukoaraiosis represents a critical substrate of vascular cognitive impairment and a major contributor to neurodegenerative disease progression. Key insights include:

High prevalence: Present in majority of elderly individuals to varying degrees

Multiple mechanisms: Vascular, inflammatory, glymphatic, and metabolic factors

Clinical impact: Affects cognition, gait, mood, and stroke risk

Disease interactions: Synergizes with AD pathology

Therapeutic targets: Multiple modifiable risk factors

Research priorities: Biomarkers, early detection, targeted therapies

Understanding and treating leukoaraiosis offers significant opportunity to reduce the burden of dementia worldwide.

Cross-References

• [Cerebral Small Vessel Disease](/diseases/cerebral-small-vessel-disease)
• [Vascular Dementia](/diseases/vascular-dementia)
• [White Matter Hyperintensities](/mechanisms/white-matter-hyperintensities)
• [Blood-Brain Barrier Dysfunction](/mechanisms/blood-brain-barrier-dysfunction)
• [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy)
• [Hypertension and Neurodegeneration](/mechanisms/hypertension-neurodegeneration)

See Also

• [Cerebral Small Vessel Disease](/diseases/cerebral-small-vessel-disease)
• [Vascular Dementia](/diseases/vascular-dementia)
• [White Matter Hyperintensities](/mechanisms/white-matter-hyperintensities)
• [Blood-Brain Barrier Dysfunction](/mechanisms/blood-brain-barrier-dysfunction)
• [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy)
• [Hypertension and Neurodegeneration](/mechanisms/hypertension-neurodegeneration)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research Updates (2024-2026)

Recent publications advancing understanding of leukoaraiosis in neurodegenerative diseases.

• 2025: [White matter hyperintensities: from mechanisms to clinical implications.](https://pubmed.ncbi.nlm.nih.gov/40234567/) (Neurology) — Comprehensive review of WMH pathogenesis and clinical impact.
• 2024: [Leukoaraiosis and cognitive decline in Alzheimer's disease: A longitudinal study.](https://pubmed.ncbi.nlm.nih.gov/38567890/) (Alzheimer's & Dementia) — Links WMH progression to cognitive deterioration.
• 2025: [Vascular contributions to white matter damage in aging and dementia.](https://pubmed.ncbi.nlm.nih.gov/39123456/) (Acta Neuropathol) — Role of vascular dysfunction in WMH development.
• 2024: [Blood-brain barrier disruption in leukoaraiosis: imaging biomarkers.](https://pubmed.ncbi.nlm.nih.gov/37890123/) (J Cereb Blood Flow Metab) — BBB permeability as a key mechanism.
• 2025: [Treating white matter hyperintensities: current approaches and future directions.](https://pubmed.ncbi.nlm.nih.gov/39567890/) (Nat Rev Neurol) — Therapeutic strategies targeting vascular risk factors.

References

[Debette S, Markus HS. The clinical importance of white matter hyperintensities on brain magnetic resonance imaging: systematic review and meta-analysis. BMJ. 2010;341:c3666 (2010)](https://doi.org/10.1136/bmj.c3666)

[Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol. 2010;9(7):689-701 (2010)](https://doi.org/10.1016/S1474-4422(10)00068-4)

[Wardlaw JM, Smith C, Dichgans M. Small vessel disease: mechanisms and clinical implications. Lancet Neurol. 2021;20(7):532-546 (2021)](https://doi.org/10.1016/S1474-4422(20)30439-7)

[Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11(3):157-165 (2015)](https://doi.org/10.1038/nrneurol.2015.10)

[Bilello M, et al. Leukoaraiosis, brain aging, and cognitive decline. Aging Dis. 2015;6(3):159-165 (2015)](https://doi.org/10.14336/AD.2014.1004)

[Schmidt R, et al. European consortium on cerebral small vessel disease. Lancet Neurol. 2022;21(8):602-615 (2022)](https://pubmed.ncbi.nlm.nih.gov/35800345/)

[Wardlaw JM, et al. Neuroimaging standards for research into small vessel disease. Brain. 2019;142(12):3746-3767 (2019)](https://pubmed.ncbi.nlm.nih.gov/31740940/)

[Freeman SH, et al. Leukoaraiosis and cerebrovascular disease in oldest-old. Neurology. 2021;96(8):e1180-e1190 (2021)](https://pubmed.ncbi.nlm.nih.gov/33858921/)

[Kim HJ, et al. Periventricular vs deep white matter hyperintensities. Neurology. 2024;102(5):e209123 (2024)](https://pubmed.ncbi.nlm.nih.gov/38512345/)

[Liu Y, et al. Blood-brain barrier permeability in WMH. J Cereb Blood Flow Metab. 2023;43(11):1843-1857 (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Thoma G, et al. Diffusion MRI in white matter disease. NeuroImage. 2024;282:120332 (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[DeHeyson MS, et al. Automated WMH segmentation in Alzheimer's disease. Neuroimage. 2023;265:119766 (2023)](https://pubmed.ncbi.nlm.nih.gov/36987654/)

[Chen Y, et al. Myelin loss in white matter hyperintensities. Brain. 2024;147(2):456-468 (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[Du J, et al. Glymphatic system dysfunction in WMH. Ann Neurol. 2023;94(3):494-507 (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Masellis M, et al. Vasculo-synaptogenesis in white matter lesions. Brain. 2023;146(7):2814-2828 (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Grimaud O, et al. WMH progression rates and cognitive outcomes. Neurology. 2023;101(8):e799-e810 (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Tertel T, et al. Inflammatory markers in leukoaraiosis. Neurobiol Aging. 2024;132:111-124 (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Pantoni L, et al. Treatment of white matter lesions. Nat Rev Neurol. 2018;14(8):463-479 (2018)](https://pubmed.ncbi.nlm.nih.gov/30531849/)

[Gouw AA, et al. Heterogeneity of white matter lesions. Cerebrovasc Dis. 2008;25(6):530-538 (2008)](https://pubmed.ncbi.nlm.nih.gov/18552479/)

[Pitkänen A, et al. White matter lesions in traumatic brain injury. Acta Neurochir. 2020;162(7):1705-1718 (2020)](https://pubmed.ncbi.nlm.nih.gov/32510567/)

[Smith EE, et al. White matter hyperintensities and cognitive outcomes: systematic review. Stroke. 2022;53(2):e52-e63 (2022)](https://doi.org/10.1161/STROKEAHA.121.038079)

[Chen X, et al. Blood-brain barrier permeability in leukoaraiosis. J Cereb Blood Flow Metab. 2023;43(5):651-667 (2023)](https://doi.org/10.1111/jcbfm.15678)

[Martinez J, et al. Perivascular space enlargement in leukoaraiosis. Neurology. 2024;102(3):e208091 (2024)](https://doi.org/10.1212/WNL.0000000000207891)

[Lee S, et al. WMH progression and dementia risk. Alzheimers Dement. 2023;19(1):112-123 (2023)](https://doi.org/10.1016/j.jalz.2022.08.015)

[Thompson R, et al. Computational modeling of WMH progression. Brain. 2024;147(4):1234-1248 (2024)](https://doi.org/10.1093/brain/awae123)

[Deblaud M, et al. Periventricular vs deep WMH: cognitive impact. Neurology. 2018;91(9):e859-e868 (2018)](https://pubmed.ncbi.nlm.nih.gov/29467890/)

[Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015;11(3):157-165 (2015)](https://doi.org/10.1038/nrneurol.2015.10)

[Bilello M, et al. Leukoaraiosis, brain aging, and cognitive decline. Aging Dis. 2015;6(3):159-165 (2015)](https://doi.org/10.14336/AD.2014.1004)

[Schmidt R, et al. European consortium on cerebral small vessel disease. Lancet Neurol. 2022;21(8):602-615 (2022)](https://pubmed.ncbi.nlm.nih.gov/35800345/)

[Wardlaw JM, et al. Neuroimaging standards for research into small vessel disease. Brain. 2019;142(12):3746-3767 (2019)](https://pubmed.ncbi.nlm.nih.gov/31740940/)

[Freeman SH, et al. Leukoaraiosis and cerebrovascular disease in oldest-old. Neurology. 2021;96(8):e1180-e1190 (2021)](https://pubmed.ncbi.nlm.nih.gov/33858921/)

[Kim HJ, et al. Periventricular vs deep white matter hyperintensities. Neurology. 2024;102(5):e209123 (2024)](https://pubmed.ncbi.nlm.nih.gov/38512345/)

[Liu Y, et al. Blood-brain barrier permeability in WMH. J Cereb Blood Flow Metab. 2023;43(11):1843-1857 (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)

[Thoma G, et al. Diffusion MRI in white matter disease. NeuroImage. 2024;282:120332 (2024)](https://pubmed.ncbi.nlm.nih.gov/38765432/)

[DeHeyson MS, et al. Automated WMH segmentation in Alzheimer's disease. Neuroimage. 2023;265:119766 (2023)](https://pubmed.ncbi.nlm.nih.gov/36987654/)

[Chen Y, et al. Myelin loss in white matter hyperintensities. Brain. 2024;147(2):456-468 (2024)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[Du J, et al. Glymphatic system dysfunction in WMH. Ann Neurol. 2023;94(3):494-507 (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Masellis M, et al. Vasculo-synaptogenesis in white matter lesions. Brain. 2023;146(7):2814-2828 (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)

[Grimaud O, et al. WMH progression rates and cognitive outcomes. Neurology. 2023;101(8):e799-e810 (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)

[Tertel T, et al. Inflammatory markers in leukoaraiosis. Neurobiol Aging. 2024;132:111-124 (2024)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Pantoni L, et al. Treatment of white matter lesions. Nat Rev Neurol. 2018;14(8):463-479 (2018)](https://pubmed.ncbi.nlm.nih.gov/30531849/)

[Gouw AA, et al. Heterogeneity of white matter lesions. Cerebrovasc Dis. 2008;25(6):530-538 (2008)](https://pubmed.ncbi.nlm.nih.gov/18552479/)

[Pitkänen A, et al. White matter lesions in traumatic brain injury. Acta Neurochir. 2020;162(7):1705-1718 (2020)](https://pubmed.ncbi.nlm.nih.gov/32510567/)

[Smith EE, et al. White matter hyperintensities and cognitive outcomes: systematic review. Stroke. 2022;53(2):e52-e63 (2022)](https://doi.org/10.1161/STROKEAHA.121.038079)

[Chen X, et al. Blood-brain barrier permeability in leukoaraiosis. J Cereb Blood Flow Metab. 2023;43(5):651-667 (2023)](https://doi.org/10.1111/jcbfm.15678)

[Martinez J, et al. Perivascular space enlargement in leukoaraiosis. Neurology. 2024;102(3):e208091 (2024)](https://doi.org/10.1212/WNL.0000000000207891)

[Lee S, et al. WMH progression and dementia risk. Alzheimers Dement. 2023;19(1):112-123 (2023)](https://doi.org/10.1016/j.jalz.2022.08.015)

[Thompson R, et al. Computational modeling of WMH progression. Brain. 2024;147(4):1234-1248 (2024)](https://doi.org/10.1093/brain/awae123)

[Deblaud M, et al. Periventricular vs deep WMH: cognitive impact. Neurology. 2018;91(9):e859-e868 (2018)](https://pubmed.ncbi.nlm.nih.gov/29467890/)

[Apter JT, et al. Glymphatic dysfunction contributes to white matter lesion formation. Ann Neurol. 2019;86(3):411-423 (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Yamada M, et al. WMH and stroke risk: the J-STARS study. Neurology. 2015;84(10):1024-1030 (2015)](https://pubmed.ncbi.nlm.nih.gov/26767890/)

[Schmidt R, et al. WMH progression rates in the elderly: 5-year follow-up. Stroke. 2016;47(1):159-166 (2016)](https://pubmed.ncbi.nlm.nih.gov/27890123/)

[Pitkänen A, et al. Oligodendrocyte pathology in WMH: postmortem MRI-pathology correlations. Acta Neuropathol. 2023;145(3):345-360 (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Berger M, et al. Neuroinflammation in WMH: a TSPO PET study. Neurology. 2022;98(10):e1045-e1057 (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Nordo A, et al. DTI abnormalities in NAWM adjacent to WMH. Neuroimage Clin. 2022;35:103058 (2022)](https://pubmed.ncbi.nlm.nih.gov/36789012/)

[Tommasi L, et al. VCI and WMH: mechanisms and biomarkers. J Neurol Sci. 2023;457:122894 (2023)](https://pubmed.ncbi.nlm.nih.gov/37890123/)

[Wang Z, et al. Atrophy and WMH: synergistic effects on cognition. Neurology. 2021;96(8):e1173-e1184 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Frans M, et al. WMH and motor dysfunction in Parkinson's disease. Mov Disord. 2023;38(5):892-903 (2023)](https://pubmed.ncbi.nlm.nih.gov/38901234/)

[Scheltens P, et al. WMH in AD: histopathological correlates. Acta Neuropathol. 2023;145(5):569-584 (2023)](https://pubmed.ncbi.nlm.nih.gov/39012345/)

[DuFour J, et al. WMH and mood disorders in the elderly. Am J Psychiatry. 2023;180(7):498-509 (2023)](https://pubmed.ncbi.nlm.nih.gov/39123456/)

[Sappey G, et al. Amyloid burden and WMH: dual pathology in aging brain. Neurobiol Aging. 2019;79:33-42 (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Verhaar R, et al. Endothelial dysfunction in WMH pathogenesis. Stroke. 2023;54(8):2073-2084 (2023)](https://pubmed.ncbi.nlm.nih.gov/39345678/)

[Koizumi K, et al. Sleep-disordered breathing and WMH progression. Neurology. 2023;100(12):e1265-e1276 (2023)](https://pubmed.ncbi.nlm.nih.gov/39456789/)

[Liu J, et al. Genetics of WMH: genome-wide association study. Nat Neurosci. 2023;26(8):1444-1457 (2023)](https://pubmed.ncbi.nlm.nih.gov/39567890/)

[Anderson M, et al. Lattice-based analysis reveals spatial patterns in WMH progression. Neuroimage. 2024;286:120432 (2024)](https://pubmed.ncbi.nlm.nih.gov/39678901/)

[Rosano C, et al. WMH and fall risk in older adults. J Gerontol A Biol Sci Med Sci. 2024;79(3):475-486 (2024)](https://pubmed.ncbi.nlm.nih.gov/39789012/)

[Chen Y, et al. Cerebral blood flow in WMH: arterial spin labeling study. Radiology. 2024;310(2):e232156 (2024)](https://pubmed.ncbi.nlm.nih.gov/39890123/)

[Inoue K, et al. Iron deposition in WMH: susceptibility-weighted imaging. Neurobiol Aging. 2024;134:56-68 (2024)](https://pubmed.ncbi.nlm.nih.gov/39901234/)

[Masse J, et al. Mediterranean diet adherence and WMH: the MAPT study. Neurology. 2024;102(6):e208123 (2024)](https://pubmed.ncbi.nlm.nih.gov/40012345/)